Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
Kanta Horie, Gemma Salvadó, Nicolas R. Barthélemy, et al.
Nature Medicine (2023) Vol. 29, Iss. 8, pp. 1954-1963
Open Access | Times Cited: 118

Showing 1-25 of 118 citing articles:

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Clifford R. Jack, J. Scott Andrews, Thomas G. Beach, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5143-5169
Open Access | Times Cited: 496
Tau-targeting therapies for Alzheimer disease: current status and future directions
Erin E. Congdon, Changyi Ji, Amber M. Tetlow, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 12, pp. 715-736
Closed Access | Times Cited: 122
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Adam L. Boxer, Reisa A. Sperling
Cell (2023) Vol. 186, Iss. 22, pp. 4757-4772
Open Access | Times Cited: 78
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 7, pp. 426-439
Open Access | Times Cited: 70
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies
Niklas Mattsson, Lyduine E. Collij, Erik Stomrud, et al.
JAMA Neurology (2023) Vol. 81, Iss. 1, pp. 69-69
Closed Access | Times Cited: 67
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
Giovanni B. Frisoni, Cristina Festari, Federico Massa, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 3, pp. 302-312
Open Access | Times Cited: 55
Biomarker-based staging of Alzheimer disease: rationale and clinical applications
Joseph Therriault, Suzanne E. Schindler, Gemma Salvadó, et al.
Nature Reviews Neurology (2024) Vol. 20, Iss. 4, pp. 232-244
Closed Access | Times Cited: 55
APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread
Yun Chen, Sihui Song, Samira Parhizkar, et al.
Cell (2023) Vol. 187, Iss. 2, pp. 428-445.e20
Open Access | Times Cited: 50
Disease staging of Alzheimer’s disease using a CSF-based biomarker model
Gemma Salvadó, Kanta Horie, Nicolas R. Barthélemy, et al.
Nature Aging (2024) Vol. 4, Iss. 5, pp. 694-708
Open Access | Times Cited: 39
Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset
Yan Li, Daniel Yen, Rachel Hendrix, et al.
Annals of Neurology (2024) Vol. 95, Iss. 5, pp. 951-965
Open Access | Times Cited: 36
Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort
Augusto J. Mendes, Federica Ribaldi, Aurélien Lathuilière, et al.
Journal of Neurology (2024) Vol. 271, Iss. 4, pp. 2053-2066
Open Access | Times Cited: 29
Blood-based biomarkers in Alzheimer’s disease – moving towards a new era of diagnostics
Burak Arslan, Henrik Zetterberg, Nicholas J. Ashton
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 6, pp. 1063-1069
Open Access | Times Cited: 24
Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer’s disease
Hu Shun, Liding Zhang, Ying Su, et al.
Science Advances (2024) Vol. 10, Iss. 13
Open Access | Times Cited: 21
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment
Shorena Janelidze, Nicolas R. Barthélemy, Gemma Salvadó, et al.
JAMA Neurology (2024) Vol. 81, Iss. 9, pp. 947-947
Closed Access | Times Cited: 21
Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology
Suzanne E. Schindler, Kellen K. Petersen, Benjamin Saef, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 11, pp. 8074-8096
Open Access | Times Cited: 21
Disentangling tau: One protein, many therapeutic approaches
Courtney Lane‐Donovan, Adam L. Boxer
Neurotherapeutics (2024) Vol. 21, Iss. 2, pp. e00321-e00321
Open Access | Times Cited: 18
Advances in Alzheimer's disease: A multifaceted review of potential therapies and diagnostic techniques for early detection
Monika Sharma, Pankaj Pal, Sukesh Kumar Gupta
Neurochemistry International (2024) Vol. 177, pp. 105761-105761
Closed Access | Times Cited: 16
Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Alzheimer s & Dementia (2025)
Open Access | Times Cited: 9
Second-generation anti-amyloid monoclonal antibodies for Alzheimer’s disease: current landscape and future perspectives
Byeong‐Hyeon Kim, Sujin Kim, Yunkwon Nam, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup
Gil D. Rabinovici, D. S. Knopman, Javier Arbizu, et al.
Journal of Nuclear Medicine (2025), pp. jnumed.124.268756-jnumed.124.268756
Closed Access | Times Cited: 2
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use
Michael Schöll, Agathe Vrillon, Takeshi Ikeuchi, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100056-100056
Open Access | Times Cited: 2
The Common Alzheimer's Disease Research Ontology (CADRO) for biomarker categorization
Amanda M. Leisgang Osse, Jefferson W. Kinney, Jeffrey L. Cummings
Alzheimer s & Dementia Translational Research & Clinical Interventions (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 2
Challenges in the practical implementation of blood biomarkers for Alzheimer’s disease
Michael Schöll, Inge M.W. Verberk, Marta del Campo, et al.
The Lancet Healthy Longevity (2024) Vol. 5, Iss. 10, pp. 100630-100630
Open Access | Times Cited: 13
A critical appraisal of blood-based biomarkers for Alzheimer’s disease
Simone Lista, Mark Mapstone, Filippo Caraci, et al.
Ageing Research Reviews (2024) Vol. 96, pp. 102290-102290
Closed Access | Times Cited: 12
Alzheimer’s disease biomarkers and their current use in clinical research and practice
T. Hunter, Luís E. Santos, Fernanda Tovar‐Moll, et al.
Molecular Psychiatry (2024)
Closed Access | Times Cited: 12
Page 1 - Next Page

Scroll to top